The COVID-19 Immunity Task Force Helping guide Canada’s response to the COVID-19 pandemic
Helping to Guide Canada’s Epidemic Response2021-12-02T17:00:28-05:00

The COVID-19 Immunity Task Force’s mandate

On April 23, 2020, the Government of Canada launched the COVID-19 Immunity Task Force (CITF). The Task Force’s mandate is to catalyze, support, fund and harmonize knowledge on SARS-CoV-2 immunity for federal, provincial, and territorial decision-makers in their efforts to protect Canadians and minimize the impact of the COVID-19 pandemic.

Priority Areas of Research

Immune Science

Advancing our understanding of immunity: Is immunity a given once someone has had COVID-19? How long does it last? Are there factors that make immunity wane faster?

Seroprevalence Studies

Collecting serologic data: How many Canadians have SARS-CoV-2 antibodies, suggesting they’ve had COVID-19? Are some populations more likely to get SARS-CoV-2 and how could we better protect them?

Immune Testing

Fine-tuning methods for accurate serologic testing: Which tests can detect the new variants? Are there antibody tests that can be developed giving us results in minutes?

Vaccine Surveillance

Supporting research partners from across Canada in a new collaboration that will study vaccine effectiveness and safety in the population at large and in high-priority groups.

Boosters

Understanding when and if the general population and sub-groups such as long-term care residents, racialized communities or Indigenous Peoples need booster shots.

Pediatric Vaccination

Researching the safety, effectiveness and immunogenicity of vaccines in children under 12 to help inform the roll out of vaccines.

Immunity Modelling

Modelling trends in the overall immunity across Canada arising from infection and vaccination.

 width=

Cross-cutting themes

Generating comparable measures of immunity, better understanding of correlates of protection, and improving data sharing across Canada.

New CITF Publication!

CITF Monthly Review’s First Issue

We’ve launched our new monthly online magazine, CITF Monthly Review, to bring you the most thought-provoking results from our funded studies, our latest conclusions as drawn from the CITF’s very own modelling efforts, and more. This month’s issue features a commentary from our CITF experts on the benefits of pediatric vaccination.
Desktop version Mobile version

CITF-funded Research Results

Antibody wane being observed and breakthrough infections rare: Latest Canadian Blood Services report

General population studies|

In their latest report, Canadian Blood Services reveals that 97% of blood donors sampled in September had evidence of antibodies against SARS-CoV-2 acquired through immunization with at least one vaccine dose and/or a past infection. This number is largely driven by vaccination as infection-acquired seroprevalence remained low in September - [...]

How adolescents with inflammatory bowel disease treated with immunosuppressive drugs respond to COVID-19 vaccination

Pediatrics|

In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive [...]

Latest News

SeroTracker expands its SARS-CoV-2 serosurveillance hub

CITF-funded SeroTracker has added to its knowledge hub that tracks findings from SARS-CoV-2 serosurveillance efforts worldwide and in Canada. Peruse the maps and graphs and see how many people in this country (by province & territory as well) and around the world are estimated to have been infected with or vaccinated against this coronavirus to date (based on published research).
Explore SeroTracker

SeroTracker dashboard

What is serosurveillance and why is it important?

Serosurveillance is a common way of seeing how many people have been previously infected with a certain infectious agent, in this case SARS-CoV-2, the virus causing COVID-19. Blood samples from hundreds of thousands of Canadians are currently being tested to check levels of antibodies, which suggest a past infection. Serosurveillance can also help determine priority groups for vaccination and will be used to monitor the effectiveness of vaccines.

What does “vaccine surveillance” mean?

Vaccine surveillance includes studies of vaccine effectiveness (how good vaccines are at preventing severe disease, new infections, and transmission) and safety (identifying and quantifying the vaccine adverse effects). Although vaccines go through numerous trials before being approved for use, it is crucial to monitor their effectiveness and safety within a broader population and with various population groups (children, pregnant women, elderly, etc.).
See all FAQs

What is serosurveillance and why is it important?

Serosurveillance is a common way of seeing how many people have been previously infected with a certain infectious agent, in this case SARS-CoV-2, the virus causing COVID-19. Blood samples from hundreds of thousands of Canadians are currently being tested to check levels of antibodies, which suggest a past infection. Serosurveillance can also help determine priority groups for vaccination and will be used to monitor the effectiveness of vaccines.

What does “vaccine surveillance” mean?

Vaccine surveillance includes studies of vaccine effectiveness (how good vaccines are at preventing severe disease, new infections, and transmission) and safety (identifying and quantifying the vaccine adverse effects). Although vaccines go through numerous trials before being approved for use, it is crucial to monitor their effectiveness and safety within a broader population and with various population groups (children, pregnant women, elderly, etc.).
See all FAQs

Sign up for our newsletter!

Spotlight on CITF-funded Research

Seeking information on vaccine procurement and advice?

For those seeking information on vaccine procurement and advice, please note that it is the COVID-19 Vaccine Task Force that advises the federal government on COVID-19 vaccine procurement and the National Advisory Committee on Immunization that advises the federal, provincial and territorial governments on vaccine delivery policy and priorities.

Go to Top